Immune reset: CAR T-Cells take on lupus and vasculitis
NCT ID NCT06152172
First seen Feb 19, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This early-stage study tests a single dose of KYV-101, a personalized CAR T-cell therapy, in up to 24 adults with certain autoimmune diseases (like lupus nephritis and vasculitis). The goal is to see if it is safe and can reduce disease activity by targeting and destroying faulty B cells. Participants will be followed for two years after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the Universithy of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.